ARV-766 for Hormone-Refractory Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Hormone-Refractory Prostate CancerARV-766 - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial will test a new drug, ARV-766, to see if it is safe and effective in treating men with prostate cancer that has spread and is resistant to hormone therapy.

Eligible Conditions
  • Hormone-Refractory Prostate Cancer

Treatment Effectiveness

Study Objectives

7 Primary · 0 Secondary · Reporting Duration: 28 Days

12 Weeks
Part B: To evaluate the clinical anti-tumor activity of ARV-766 in patients with mCRPC
28 Days
Incidence of Dose Limiting Toxicities of ARV-766
Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-766
Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-766
Part A: Incidence of Dose Limiting Toxicities of ARV-766
Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-766
Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-766

Trial Safety

Trial Design

3 Treatment Groups

ARV-766 Part A
1 of 3
ARV-766 Part B
1 of 3
ARV-766
1 of 3

Experimental Treatment

150 Total Participants · 3 Treatment Groups

Primary Treatment: ARV-766 · No Placebo Group · Phase 1 & 2

ARV-766 Part A
Drug
Experimental Group · 1 Intervention: ARV-766 Part A · Intervention Types: Drug
ARV-766 Part B
Drug
Experimental Group · 1 Intervention: ARV-766 Part B · Intervention Types: Drug
ARV-766
Drug
Experimental Group · 1 Intervention: ARV-766 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days

Who is running the clinical trial?

Arvinas Androgen Receptor, Inc.Lead Sponsor
3 Previous Clinical Trials
296 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have received at least one but no more than three prior second generation anti-androgen agents (e.g.
Participants must have received no more than two prior chemotherapy regimens.
You have adenocarcinoma of the prostate.
You have a performance status of 0 or 1.

Who else is applying?

What state do they live in?
New York100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%